The independent platform for news, articles and advice for professionals in laboratory medicine

Navigate BioPharma and BD to collaborate on developing flow cytometry

US-based laboratory Navigate BioPharma Services has announced a strategic collaboration with medical technology company BD (Becton, Dickinson and Company) to develop and commercialise flow cytometry-based companion diagnostics and tools for clinical decisions.

Navigate BioPharma is a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications.

The collaboration aims to leverage the complementary expertise and capabilities of both companies to provide end-to-end solutions for pharmaceutical and biotechnology companies developing novel therapies that require companion diagnostics, tests intended to match patients with life-changing treatments, and critical clinical trial applications that utilise flow cytometry. Importantly, this collaboration aims to address a critical gap in the clinical trial field for an integrated solution provider from method development to commercialisation.

"Flow cytometry-based companion diagnostics can help identify patients who are most likely to benefit from a specific therapy, monitor their response to treatment, and optimise dosing and safety from a patient sample," said Dr Shabnam Tangri, Chief Scientific Officer at Navigate BioPharma. "Advances in flow cytometry technology made by BD can enable in vitro diagnostics (IVD) testing to be executed with accuracy, automation and standardisation across all elements of the workflow."

Vipin Bhambhani, VP of Clinical Flow Solutions, BD Biosciences added: "Flow cytometry is a powerful technique that can enable high-sensitivity, affordable testing with fast turnaround time. The collaboration will combine Navigate BioPharma's extensive experience in designing and validating biomarker assays for clinical trials and regulatory submissions with the broad BD portfolio of flow cytometry instruments, reagents, software, and IVD development services, to potentially accelerate the delivery of innovative personalised therapies to patients who need them most."

The parties intend to collaborate with biopharma organisations in the following areas:

  • Accelerating the delivery of personalised therapies to patients by using biomarker-based assays as an essential clinical trial or companion diagnostic tool for cancer and other diseases.
  • Addressing the latest health authority expectations for high-sensitivity minimal residual disease (MRD) monitoring assays as surrogate endpoints.
  • Providing flexible and integrated solutions that can help collaborators achieve their clinical and regulatory goals by leveraging the capabilities of flow cytometry.
  • Expanding the range of therapeutic options and biomarkers that can be analysed, including complex target and drug combinations, rare cell populations, cell signalling and function.
  • Increasing the effectiveness of biomarker profiling and enhancing the quality and efficiency of the companion diagnostic development process by utilising the cutting-edge technologies and services offered by both companies, and Navigate BioPharma's expertise in developing specialty high-complexity and high-dimension flow cytometry and execution through regulated clinical trial testing.

Navigate BioPharma Services is an independent subsidiary in the Novartis group of companies, providing innovative biomarker and specialty bioanalytic solutions for clinical development and companion diagnostic applications. Over the past decade, Navigate BioPharma has built and developed an exclusive library of assays, methodologies, and biomarker solutions.

 

Upcoming Events

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025